HCV NS-3 serine protease inhibitors

Compounds of the formula, where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site...

Full description

Saved in:
Bibliographic Details
Main Authors RAKOS, LASZLO, AYESA, SUSANA, CLASSON, BJORN, JOHANSSON, PER-OLA, THORSTENSSON, FREDRIK, KVARNSTROM, INGEMAR, SAMUELSSON, BERTIL, ROSENQUIST, ASA
Format Patent
LanguageChinese
English
Published 01.12.2005
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Compounds of the formula, where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
Bibliography:Application Number: TW200594102721